Pfizer has announced the commercial launch of its bispecific antibody elranatamab in India for the treatment of adults with relapsed or refractory multiple myeloma, offering a new option for patients who have exhausted multiple prior therapies. The therapy is indicated for patients who have received at least four previous lines of treatment, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Elranatamab is a fixed-dose subcutaneous injection that is globally marketed under the brand name Elrexfio, which first received approval from the US Food and Drug Administration (FDA) in 2023. In India, the product will be available under the brand name Elduxio, further expanding Pfizer’s oncology portfolio in the country. The medicine follows a weekly dosing schedule initially, which can be shifted to every-other-week administration after 24 weeks in patients who respond, helping reduce treatment burden over time.
Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager designed to bring T cells into proximity with myeloma cells to trigger targeted cancer cell killing. In the pivotal Phase 3 MagnetisMM-3 study, the drug demonstrated a median overall survival of 24.6 months and a median progression-free survival of 17.2 months in heavily pre-treated patients, highlighting its potential to improve outcomes in this difficult-to-treat population.
In India, the approval of Elduxio comes with a requirement for a post-marketing surveillance study involving at least 100 patients to further evaluate its safety and effectiveness in the local population. While Pfizer has not yet disclosed the pricing for the drug in India, the launch is expected to enhance access to advanced immunotherapy for multiple myeloma and strengthen treatment options in tertiary cancer centres across the country.
